The Selective Peroxisomal Proliferator-Activated Receptor-Gamma Agonist Has an Additive Effect on Plaque Regression in Combination with Simvastatin in Experimental Atherosclerosis: In Vivo Study by High-Resolution Magnetic Resonance Imaging

Journal of the American College of Cardiology

Volumn 43, Issue 3, 2004, Pages 464-473

  Corti, Roberto ^a   Osende, Julio I ^a   Fallon, John T ^a   Fuster, Valentin ^a   Mizsei, Gabor ^a   Jneid, Hani ^a   Wright, Samuel D ^b   Chaplin, William F ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CELL COUNT; CHEMICAL COMPOSITION; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DRUG SELECTIVITY; HISTOPATHOLOGY; LIPID BLOOD LEVEL; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0842309101     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.08.048     Document Type: Article

References (41)

1. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit impact of statin trials . Circulation. 97:1998;946-952.
2. Sacks F.M., Moye L.A., Davis B.R., et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol And Recurrent Events trial. Circulation. 97:1998;1446-1452.
3. The MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
4. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:2001;365-372.
5. Sukhova G.K., Williams J.K., Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 22:2002;1452-1458.
6. Callister T.Q., Raggi P., Cooil B., Lippolis N.J., Russo D.J. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 339:1998;1972-1978.
7. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques implications for plaque stabilization . Circulation. 103:2001;926-933.
8. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI a case-control study . Arterioscler Thromb Vasc Biol. 21:2001;1623-1629.
9. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions a longitudinal study by high-resolution, noninvasive magnetic resonance imaging . Circulation. 104:2001;249-252.
10. Hsueh W.A., Jackson S., Law R.E. Control of vascular cell proliferation and migration by PPAR-gamma a new approach to the macrovascular complications of diabetes . Diabetes Care. 24:2001;392-397.
11. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. Macrophages in human atheroma contain PPAR-gamma differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPAR-gamma activation in mononuclear phagocytes in vitro . Am J Pathol. 153:1998;17-23.
12. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 95:1998;7614-7619.
13. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
14. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
15. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 101:2000;235-238.
16. Marx N., Bourcier T., Sukhova G.K., Libby P., Plutzky J. PPAR-gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression PPAR-gamma as a potential mediator in vascular disease . Arterioscler Thromb Vasc Biol. 19:1999;546-551.
17. Kato K., Yamada D., Midorikawa S., Sato W., Watanabe T. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism. 49:2000;662-665.
18. Satoh H., Tsukamoto K., Hashimoto Y., et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells a new possible role of PPAR-gamma on vascular endothelial function . Biochem Biophys Res Commun. 254:1999;757-763.
19. Chinetti G., Gbaguidi F.G., Griglio S., et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 101:2000;2411-2417.
20. Fruchart J.C. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol. 88:2001;24N-29N.
21. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 106:2000;523-531.
22. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 83:1998;1818-1820.
23. Yuan C., Beach K.W., Smith L.H. Jr, Hatsukami T.S. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation. 98:1998;2666-2671.
24. Worthley S.G., Helft G., Fuster V., et al. Serial in vivo MRI documents arterial remodeling in experimental atherosclerosis. Circulation. 101:2000;586-589.
25. Helft G., Worthley S.G., Fuster V., et al. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging an in vivo study in rabbits . J Am Coll Cardiol. 37:2001;1149-1154.
26. McConnell M.V., Aikawa M., Maier S.E., Ganz P., Libby P., Lee R.T. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. Arterioscler Thromb Vasc Biol. 19:1999;1956-1959.
27. Fayad Z.A., Fallon J.T., Shinnar M., et al. Noninvasive In vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation. 98:1998;1541-1547.
28. Skinner M.P., Yuan C., Mitsumori L., et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med. 1:1995;69-73.
29. Galis Z.S., Muszynski M., Sukhova G.K., et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 75:1994;181-189.
30. Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma a potential mechanism of lesion stabilization . Circulation. 97:1998;2433-2444.
31. Helft G., Worthley S.G., Fuster V., et al. Progression and regression of atherosclerotic lesions monitoring with serial noninvasive magnetic resonance imaging . Circulation. 105:2002;993-998.
32. Fuster V., Fayad Z.A., Badimon J.J. Acute coronary syndromes biology . Lancet. 353:(Suppl II):1999;SII5-9.
33. Libby P., Aikawa M. Stabilization of atherosclerotic plaques new mechanisms and clinical targets . Nat Med. 8:2002;1257-1262.
34. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., Nakamura Y. Rapid communication inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes . J Clin Endocrinol Metab. 86:2001;3452-3456.
35. Shah P.K., Kaul S., Nilsson J., Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins an idea whose time for testing is coming, part I . Circulation. 104:2001;2376-2383.
36. Spieker L.E., Sudano I., Hurlimann D., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 105:2002;1399-1402.
37. Moore K.J., Rosen E.D., Fitzgerald M.L., et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med. 7:2001;41-47.
38. Takagi T., Akasaka T., Yamamuro A., et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus a serial intravascular ultrasound study . J Am Coll Cardiol. 36:2000;1529-1535.
39. de Dios S.T., Bruemmer D., Dilley R.J., et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation. 107:2003;2548-2550.
40. Bishop-Bailey D., Hla T., Warner T.D. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res. 91:2002;210-217.
41. Wang N., Verna L., Chen N.G., et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 277:2002;34176-34181.